Last reviewed · How we verify
153Sm-DOTMP
A radioligand targeting somatostatin receptors
A radioligand targeting somatostatin receptors Used for Prostate cancer, Neuroendocrine tumors.
At a glance
| Generic name | 153Sm-DOTMP |
|---|---|
| Also known as | CycloSam |
| Sponsor | Telix Pharmaceuticals (Innovations) Pty Limited |
| Drug class | Somatostatin receptor targeting agent |
| Target | Somatostatin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
153Sm-DOTMP is a radioligand that targets somatostatin receptors, which are overexpressed in certain types of tumors.
Approved indications
- Prostate cancer
- Neuroendocrine tumors
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain (PHASE1)
- A Dose Finding Study to Treat Bone Tumor(s) (PHASE1)
- A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 153Sm-DOTMP CI brief — competitive landscape report
- 153Sm-DOTMP updates RSS · CI watch RSS
- Telix Pharmaceuticals (Innovations) Pty Limited portfolio CI